11 August 2021 : Clinical Research
Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center
Jianquan Zhu1ABCDEF, Yu Zhang1BC, Meng Wang1BC, Zhenfa Zhang1BC, Dongsheng Yue1BC, Shichang Liu2BC, Yi Pan3BC, Changli Wang1AE*DOI: 10.12659/MSM.930738
Med Sci Monit 2021; 27:e930738
Table 6 Univariable Cox regression model of overall survival and progression-free survival in patients with squamous cell carcinoma of the lung who underwent surgery after neoadjuvant nab-paclitaxel and carboplatin (n=23).
| Variable | OS | PFS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| PR (vs non-PR) | 0.442 | (0.109–1.789) | 0.252 | 0.582 | (0.186–1.820) | 0.352 |
| MPR (vs non-MPR) | 0.525 | (0.130–2.118) | 0.365 | 0.404 | (0.108–1.513) | 0.179 |
| pCR (vs non-pCR) | 0.404 | (0.049–3.309) | 0.399 | 0.277 | (0.035–2.181) | 0.223 |
| Type of surgery | ||||||
| Bilobectomy (vs lobectomy) | 1.164 | (0.135–10.063) | 0.890 | 0.713 | (0.087–5.812) | 0.752 |
| Pneumonectomy (vs lobectomy) | 23.856 | (1.928–295.202) | 0.014 | 33.306 | (3.247–341.618) | 0.003 |
| Pneumonectomy (vs bilobectomy) | 20.482 | (1.001–419.159) | 0.050 | 46.729 | (2.436–896.455) | 0.011 |
| CI – confidence interval; HR – hazard ratio; MPR – major pathologic response; OS – overall survival; pCR – pathologic complete response; PFS – progression-free survival; PR – partial response. | ||||||